Cutaneous side effects of molecularly targeted therapies for the treatment of solid tumors

Article Details

Authors
Daniel I G Cubero MD, PhD, Beatrice Martinez Zugaib Abdalla MD, Jean Schoueri, Fabio Iazetti Lopes, Karine Corcione Turke, Jose Guzman MD, Auro Del Giglio MD, PhD, Carlos D’Apparecida Santos Machado Filho MD, PhD, Vanessa Salzano MD, Dolores Gonzalez Fabra MD

Article Type
Review

DOI
10.7573/dic.212516

Related Articles

Article Page

Abstract

Background: Currently, molecularly targeted drugs are part of the therapeutic arsenal for the treatment of many neoplasms and are responsible for improvements in the quality of life and survival of patients. Although they act on proteins and components within biochemical pathways that are expressed to a greater extent in neoplastic cells, these drugs can also interfere with the activity of normal cells.

Scope: This article reviews the cutaneous side effects of main molecularly targeted cancer therapies for solid tumors.

Findings: The use of these drugs causes side effects, and the skin is one of the most commonly affected organs. In this literature review, we discuss the adverse cutaneous effects caused by molecularly targeted drugs.

Conclusion: The identification of these reactions is important to both dermatologists and oncologists so that they properly diagnose the reaction and administer adequate treatment, which would allow greater adherence to the oncological treatment and improve patients’ quality of life.

Keywords: adverse reactions, chemotherapy, dermatology, drug-related side effects, immunotherapy, oncology, skin, targeted therapy.

Citation: Cubero DIG, Abdalla BMZ, Schoueri J, Lopes FI, Turke KC, Guzman J, Del Giglio A, Machado Filho CDS, Salzano V, Fabra DG. Cutaneous side effects of molecularly targeted therapies for the treatment of solid tumors. Drugs in Context 2018; 7: 212516. DOI: 10.7573/dic.212516

Disclosure and potential conflicts of interest: The authors declare no conflicts of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at https://www.drugsincontext.com/wp-content/uploads/2018/06/dic.212516-COI.pdf

Funding declaration: There was no funding for this manuscript.

Copyright: Copyright © 2018 Cubero DIG, Abdalla BMZ, Schoueri J, Lopes FI, Turke KC, Guzman J, Del Giglio A, Machado Filho CDS, Salzano V, Fabra DG. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2018 Cubero DIG, Abdalla BMZ, Schoueri J, Lopes FI, Turke KC, Guzman J, Del Giglio A, Machado Filho CDS, Salzano V, Fabra DG. https://doi.org/10.7573/dic.212516. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/cutaneous-side-effects-of-molecularly-targeted-therapies-for-the-treatment-of-solid-tumors

Correspondence: Daniel I G Cubero, Department of Oncology and Hematology, ABC Foundation School of Medicine. Av Principe de Gales, 821, Anexo 3 – segundo andar, Santo André/SP – Brazil, ZIP 09060-650. danielcubero@uol.com.br

Provenance: invited; externally peer reviewed.

Submitted: 15 November 2017; Peer review comments to author: 6 February 2018; Revised manuscript received: 14 May 2018; Accepted: 15 May 2018; Publication date: 17 July 2018.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252772009.

For all manuscript and submissions enquiries, contact the Editorial office dic.editorial@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF